Evidence map›Paper›PMID 35246994›Full record

ArticleJournal of veterinary internal medicine2022

Transvenous electrical cardioversion of atrial fibrillation in horses: Horse and procedural factors correlated with success and recurrence.

Ingrid Vernemmen, Glenn Van Steenkiste, Alexander Dufourni, Annelies Decloedt, Gunther van Loon

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Treatment of ventricular arrhythmias with oral sotalol in four horses.Journal of veterinary internal medicine · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ingrid VernemmenEquine Cardioteam, Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.ORCID https://orcid.org/0000-0002-8185-1450
Glenn Van SteenkisteEquine Cardioteam, Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.ORCID https://orcid.org/0000-0002-0165-5215
Alexander DufourniEquine Cardioteam, Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Annelies DecloedtEquine Cardioteam, Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.ORCID https://orcid.org/0000-0001-8129-2006
Gunther van LoonEquine Cardioteam, Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.ORCID https://orcid.org/0000-0001-5191-5241
Ghent University · BE

Funding

Fonds Wetenschappelijk Onderzoek 1S56217N
6 · The paper itself

Abstract

backgroundTransvenous electrical cardioversion (TVEC) is 1 of the main treatment options for atrial fibrillation (AF) in horses. Large-scale studies on factors affecting success and prognosis have primarily been performed in Standardbred populations. HYPOTHESIS/

objectivesTo determine factors affecting cardioversion success, cardioversion difficulty and recurrence in a predominant Warmblood study sample. ANIMALS: TVEC records of 199 horses.

methodsRetrospective study of TVEC procedures of horses admitted for AF without severe echocardiographic abnormalities. Horse and procedural factors for success and cumulative amount of energy (≤ 600 J vs > 600 J) were determined using multivariable logistic regression. A survival analysis was performed to determine risk factors for recurrence.

resultsTwo hundred and thirty-one TVEC procedures were included, with a 94.4% success rate and 31.9% recurrence rate (51/160). Mitral regurgitation (OR 0.151, 95% CI 0.032-0.715, P = .02) and AF cycle length (OR 1.05, 95% CI 1.01-1.09, P = .02) were independent determinants for success. Catheter type (OR 0.154, 95% CI 0.074-0.322, P < .001), previous AF episode (OR 3.10, 95% CI 1.20-8.01, P = .02), tricuspid regurgitation (OR 2.54, 95% CI 1.25-5.13, P = .01), and body weight (OR 1.009, 95% CI 1.003-1.015, P = .004) were significantly correlated with cumulative amount of energy delivered. Significant risk factors for recurrence after a first AF episode were sex (stallion; HR 3.05, 95% CI 1.34-6.95, P = .008), mitral regurgitation (HR 1.91, 95% CI 1.08-3.38, P = .03), and AF duration (HR 1.001, 95% CI 1.0001-1.0026, P = .04). CONCLUSIONS AND CLINICAL IMPORTANCE: Both horse and procedural factors should be considered when assessing treatment options and prognosis in horses with AF.

Indexed as

Atrial FibrillationHorse DiseasesAnimalsEchocardiographyElectric CountershockHorsesMaleRecurrenceRetrospective Studiesamiodaronearrhythmiacardiologyequinesotalol

Identifiers

PMID35246994
PMCPMC8965264
OpenAlexW4221072249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.